BIBP 3226 trifluoroacetate: Selective NPY/NPFF Antagonist for Research

Executive Summary: BIBP 3226 trifluoroacetate is a non-peptide antagonist with nanomolar affinity for neuropeptide Y Y1 (NPY Y1) and neuropeptide FF (NPFF) receptors, widely used in dissecting the NPY/NPFF system in anxiety, analgesia, and cardiovascular regulation (product information). It blocks NPFF-dependent hypothermic and anti-opioid effects in rodents and inhibits NPFF-induced suppression of cAMP production (article summary). Recent evidence implicates the NPY/Y1 receptor axis as a key driver of adipose-neural signaling in cardiac arrhythmias (Fan et al., 2024). BIBP 3226 is used to probe these mechanisms in advanced coculture models. APExBIO supplies BIBP 3226 trifluoroacetate as a research-grade reagent (SKU: B7155).

Biological Rationale

Neuropeptide Y (NPY) and neuropeptide FF (NPFF) are neuromodulators with critical roles in anxiety, pain processing, and cardiovascular regulation (Fan et al., 2024). The NPY Y1 receptor (Y1R) and NPFF receptors (NPFF1R, NPFF2R) are G protein-coupled receptors (GPCRs) expressed in the central and peripheral nervous systems. Dysregulation of these pathways is implicated in arrhythmogenesis, stress responses, and opioid tolerance. In epicardial adipose tissue (EAT), leptin stimulates sympathetic neurons to release NPY, which activates Y1R on cardiomyocytes, enhancing arrhythmogenic signals (mechanistic insights). Pharmacological inhibition of Y1R is a validated strategy to interrogate these networks.

Mechanism of Action of BIBP 3226 trifluoroacetate

BIBP 3226 trifluoroacetate is a non-peptide, selective antagonist for NPY Y1 and NPFF receptors. It binds the rat NPY Y1 receptor with a Ki of 1.1 nM, human NPFF2 receptor with Ki 79 nM, and rat NPFF receptor with Ki 108 nM (product details). Mechanistically, BIBP 3226 competes with endogenous agonists, blocking their ability to inhibit forskolin-stimulated cAMP accumulation. This antagonism prevents NPFF-induced hypothermia and anti-opioid responses in animal models. In vitro, it disrupts Y1R-mediated signaling cascades controlling calcium flux, relevant for arrhythmia studies (Fan et al., 2024).

Evidence & Benchmarks

• BIBP 3226 trifluoroacetate inhibits NPY Y1 receptor with a Ki of 1.1 nM (rat), supporting its high selectivity (product information).
• NPFF2 receptor antagonism is achieved at Ki 79 nM (human), enabling dual-system research (product information).
• Blocks NPFF-induced inhibition of cAMP in forskolin-stimulated cells, confirming antagonistic action on cAMP signaling (internal article).
• Prevents NPFF-dependent hypothermic and anti-opioid effects in rodent models, validating in vivo efficacy (internal article).
• In advanced coculture models, Y1R inhibition by BIBP 3226 blocks arrhythmogenic signaling driven by the adipose-neural axis (Fan et al., 2024).

This article extends previous reviews by integrating recent mechanistic findings from stem cell-based arrhythmia models and clarifying BIBP 3226's validated selectivity and application boundaries.

Applications, Limits & Misconceptions

BIBP 3226 trifluoroacetate is widely applied in:

• Anxiety research: Dissects NPY Y1-mediated anxiolytic pathways in rodent models and cell cultures.
• Analgesia mechanism study: Probes NPFF/NPY receptor roles in opioid tolerance and pain modulation (see discussion).
• Cardiovascular regulation research: Validates the NPY/Y1R axis as a key modulator in EAT-driven arrhythmias (Fan et al., 2024).

Common Pitfalls or Misconceptions

• BIBP 3226 does not block all NPY receptor subtypes; it is selective for Y1 and NPFF receptors (product information).
• In vivo, species-specific receptor differences may affect potency; rat and human affinities differ.
• The compound is unstable in solution at room temperature; long-term storage of prepared solutions is not recommended (APExBIO).
• BIBP 3226 should not be used to infer effects on unrelated GPCRs; off-target effects are minimal at recommended concentrations.
• It is not a peptide; do not use protocols requiring peptide-based ligands.

Workflow Integration & Parameters

BIBP 3226 trifluoroacetate (APExBIO, B7155) is supplied as an off-white solid (molecular weight: 587.59, formula: C29H32F3N5O5). Preparation and use should follow validated protocols:

Protocol Parameters

• Stock solution preparation: Dissolve in DMSO to ≥78 mg/mL or in ethanol to ≥73.2 mg/mL; for water, use ultrasonic assistance for ≥12.13 mg/mL (product specification).
• Storage: Store powder at -20°C. Avoid repeated freeze-thaw cycles. Store solutions short-term at 4°C, use immediately for experiments.
• In vitro Y1R/NPFF antagonism: Typical working concentrations range from 1–100 nM for cell-based assays, based on receptor Ki values.
• In vivo rodent studies: Dosing regimens should be optimized based on published pharmacokinetics and experimental endpoints (workflow detail).
• Arrhythmia model integration: Add to coculture systems of sympathetic neurons, adipocytes, and cardiomyocytes at 10–100 nM to investigate adipose-neural signaling (Fan et al., 2024).

Conclusion & Outlook

BIBP 3226 trifluoroacetate is a validated, high-affinity antagonist for NPY Y1 and NPFF receptors, enabling mechanistic dissection of neuropeptide signaling in anxiety, pain, and cardiovascular research. Recent coculture studies confirm the therapeutic relevance of the NPY/Y1R axis in arrhythmia, with BIBP 3226 serving as an essential tool for causal interrogation. APExBIO's B7155 product is widely used for these applications. Future research will refine our understanding of the adipose-neural axis, but the current evidence base positions BIBP 3226 trifluoroacetate as a gold standard for selective NPY/NPFF system interrogation (Fan et al., 2024).

For further details on product handling and advanced experimental workflows, see the APExBIO product page and recent comparative analyses (review).